
News|Articles|October 1, 2006
Valsartan appears more effective than amlodipine in preventing HF, diabetes in patients with hypertension
An angiotensin receptor blocker (ARB) valsartan-based regimen offered advantages over a calcium channel blocker (CCB) amlodipine-based regimen in preventing heart failure (HF) and diabetes in patients with hypertension, according to results of an analysis published in Hypertension.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
3
Don’t let ‘sleepmaxxing’ keep you up at night: Results from the 2025 American Academy of Sleep Medicine survey on sleep tracking
4
Myqorzo is now available for rare heart condition at a $108,400 annual price
5























